Novo Nordisk Lowers 2025 Forecast Amid Sluggish Wegovy Sales Despite Surpassing Profit Predictions

Novo Nordisk Lowers 2025 Forecast Amid Sluggish Wegovy Sales Despite Surpassing Profit Predictions

Novo Nordisk has reduced its anticipated sales growth for 2025 owing to lackluster demand for its leading weight-loss medication, Wegovy, despite reporting higher-than-expected profits in the first quarter.

In the first quarter ending March, the Danish pharmaceutical company reported a profit of 29.03 billion Danish kroner ($4.4 billion), outstripping the analysts' estimates of 27.8 billion kroner from an LSEG poll.

Sales figures for Wegovy, the company’s popular obesity medicine, reached 17.36 billion Danish kroner, which failed to meet the 18.51 billion Danish kroner projected by Factset's analysis earlier in the week.

Novo Nordisk’s total income, from its portfolio that includes diabetes and rare disease cures, was reported at 78.09 billion Danish kroner, marginally missing the forecast of 78.18 billion kroner.

Looking towards 2025, Novo Nordisk now projects its sales will grow between 13% to 21% using constant currency rates, a step down from its February estimate of a 16% to 24% growth.

This shift comes as the company experiences a high demand for its GLP-1 class of weight-loss drugs, which function by imitating hormones to decrease hunger.

Nonetheless, Novo Nordisk is facing challenges related to its experimental obesity drug CagriSema, with investor confidence being somewhat marred by recent developments.

The company is also navigating an increasingly competitive weight management drug market, facing other pharmaceutical contenders who are bringing forward new developments.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts